# Medical Economics of Urinary PCA3 Test for Prostate Cancer Diagnosis

> **NCT01632930** · NA · COMPLETED · sponsor: **Hospices Civils de Lyon** · enrollment: 962 (actual)

## Conditions studied

- Patients Scheduled for Prostate Biopsy Because of Increased Serum PSA and/or Abnormal Digital Rectal Examination

## Interventions

- **OTHER:** urinary PCA3 test using Progensa® PCA3 assay kit (Gen-Probe)

## Key facts

- **NCT ID:** NCT01632930
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07-02
- **Primary completion:** 2021-04-26
- **Final completion:** 2021-04-26
- **Target enrollment:** 962 (ACTUAL)
- **Last updated:** 2022-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01632930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01632930, "Medical Economics of Urinary PCA3 Test for Prostate Cancer Diagnosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01632930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*